Anifrolumab (anifrolumab) is an antagonist human monoclonal antibody that targets interferon a receptor 1 (IFNAR1). Anifrolumab has been developed to treat autoimmune diseases and is currently in clinical trials. To decipher the molecular basis of its mechanism of action, we engaged in multiple epitope mapping approaches to determine how it interacts with IFNAR1 and antagonizes the receptor. We identified the epitope of anifrolumab using enzymatic fragmentation, phage-peptide library panning and mutagenesis approaches. Our studies revealed that anifrolumab recognizes the SD3 subdomain of IFNAR1 with the critical residue R 279 . Further, we solved the crystal structure of anifrolumab Fab to a resolution of 2.3 A . Guided by our epitope mapping studies, we then used in silico protein docking of the anifrolumab Fab crystal structure to IFNAR1 and characterized the corresponding mode of binding. We find that anifrolumab sterically inhibits the binding of IFN ligands to IFNAR1, thus blocking the formation of the ternary IFN/ IFNAR1/IFNAR2 signaling complex. This report provides the molecular basis for the mechanism of action of anifrolumab and may provide insights toward designing antibody therapies against IFNAR1.
Introduction
The type I interferon (IFN) pathway plays several important roles in host defense against viral infection 1, 2 and in the pathogenesis of several autoimmune disorders. [3] [4] [5] Interferon a receptor 1 (IFNAR1), a critical component of the IFN signaling pathway, belongs to the helical cytokine class II family of receptors. It is composed of 4 fibronectin type III subdomains of »100 amino acids each, a single-span transmembrane domain, and an intracellular domain of »100 residues. 6, 7 The 4 subdomains (SD) of IFNAR1 are folded into domain 1 (SD1CSD2) and domain 2 (SD3CSD4). 8, 9 IFNAR1 forms a ternary signaling complex with IFNAR2 and type I IFN ligands, 10 which includes 14 IFN-a subtypes, IFN-b, IFN-e, IFN-k and IFN-v. 2 The formation of this ternary complex is the first step in the activation of several signal transduction pathways. Therefore, antagonizing this receptor and subsequently blocking the activation of kinases has the potential to prevent the downstream biologic effects of interferons in autoimmune diseases. 1, 2 IFNAR1 is essential for the binding to all type I IFNs 2, 11 and for mediation of IFN signals. 1, 12 The role of IFNAR1 in ligand recognition and signal complex assembly has been revealed using mutagenesis studies and IFNAR1 neutralizing antibodies. In particular, function-blocking antibodies 64G12 (SD3). 14 Interestingly, the N-terminal subdomain SD1 is a shared epitope region bound by these 3 reported antagonistic antibodies. Furthermore, studies using truncated IFNAR1 mutants demonstrated that SD1-3 are required and sufficient for IFN ligand binding, while the membrane-proximal SD4 was shown to control for an appropriate orientation of the receptor on the membrane that is required for efficient assembly of INFAR1 into the ternary signaling complex. 15 In addition, some hot-spot residues of IFNAR1 that contribute to ligand interactions were identified, and include residues 62 FSSLKLNVY 70 (SD1) and W 129 (SD2). 16 Notably, residues 278 LRV 280 in the SD3 subdomain were indicated to be important for signal transduction and antiviral activities. 16 The crystal structures of 2 IFN ternary signaling complexes have provided the structural basis for the recognition modes and heterotrimeric architectures of IFNAR1/IFNAR2/ IFNs. 17 These 2 complexes composed of ligands IFN-a2 or IFN-v exhibited almost identical overall receptor-ligand docking modes. IFNAR1 and IFNAR2 bind on opposing sides of the IFN ligands in a nearly orthogonal architecture. Consistent with the previously described mutagenesis results, IFNAR1 forms a broad interface with IFN ligands, involving residues in all 3 N-terminal subdomains SD1-3. 17 Upon ternary complex formation the SD1 subdomain of IFNAR1 undergoes a »10 A movement that "caps" the top of the IFN ligand. Specifically, residue Y 70 in SD1 directly contacts the IFN-a 2 ligand, which is consistent with mutagenesis mapping approaches that have revealed this residue to be critical for ligand binding. 16 In addition, the SD2-SD3 tandem orients like a pair of pincers interacting with IFN ligands primarily through its top and bottom loops.
MEDI546, also known as anifrolumab, is an IFNAR1-specific human monoclonal antibody (IgG 1 /k/ developed to block the type I IFN pathway. The constant domain of anifrolumab contains the triple mutations (TM) L234F/L235E/P331S for reduced antibody Fc-mediated effector functions. 18 It is currently in clinical trials for the treatment of autoimmune disorders, including scleroderma and systemic lupus erythematous (www.clinicaltrials.gov). 19, 20, 21 To understand the neutralizing activity of anifrolumab, we sought to provide a molecular basis for its mode of interaction with human IFNAR1 by identifying the corresponding epitope using multiple approaches, including enzymatic fragmentation, phage-display peptide library, and mutagenesis. We also solved the crystal structure of anifrolumab Fab and performed docking between the crystal structures of anifrolumab Fab and human IFNAR1 (PDB ID number 3S98). 17 Our studies revealed that anifrolumab binds a function-blocking epitope on IFNAR1 different than that of the previously reported IFNAR1-neutralizing antibodies, 13, 14, 22, 23 and provides a molecular basis for its antagonistic properties.
Results

Determination of anifrolumab epitope using enzymatic fragmentation
Limited proteolytic fragmentation 24 of IFNAR1 resolved with Western blot analysis and coupled with N-terminal sequencing identified a »12 kDa epitope of anifrolumab in IFNAR1 SD3-4. IFNAR1 undergoes heavy glycosylation 25 at 12 N-linked glycosylation sites, which results in a »12 kDa increase in the molecular weight of its extracellular domains from the predicted mass of »48 kDa to an apparent molecular weight of »60 kDa on a reducing SDS-PAGE gel (Fig. 1A) . Limited treatment of human IFNAR1 extracellular domain (ECD) with endoproteinase Lys-C resulted in 8 major protein bands, on a reducing SDS-PAGE, ranging from »3 to »48 kDa in size (Fig. 1A) . Western blot analysis showed 5 of the 8 resolved bands are not recognized by anifrolumab, while 3 bands corresponding to »48, 23, and 12 kDa (bands 1, 4, and 5, respectively) were detected by anifrolumab (Fig. 1A) . To determine their identities, Edman degradation 26 was performed on the 2 largest negative bands (2 and 3) and all 3 positive bands (1, 4, and 5) to identify their respective N-terminal amino acid compositions. The C-terminus for each fragment was estimated according to its observed molecular weight and in concert with the proteolytic cleavage sites C-terminal to lysine residues in the amino acid sequence. Thus, these 5 fragments (1-5) could be localized onto the linear sequence of IFNAR1 and are schematically represented in Figure 1B .
Characterizing the 2 large negative bands allowed us to eliminate portions of IFNAR1 from consideration as the anifrolumab binding epitope. The largest negative protein band (2, »40 kDa) began after the K 4 cleavage site, has the N-terminal sequence 5 SPQKVEVD 12 and ends in SD3. The other negative band (3, »32 kDa) contained 2 fragments: one began at S 5 thus sharing the same N-terminus as fragment number 2 and ended in SD3, while the second sequence downstream from the cleavage site of K 48 started with the N-terminal sequence of 49 LSGCQNI 55 and also ended in SD3 (Fig. 1B) . All three bands that were not recognized by anifrolumab contained a protein fragment from SD1-2. Therefore, the N-terminal half of IFNAR1 was excluded from the binding epitope and mapping efforts focused on SD3-4.
Analysis of the positive bands bound by anifrolumab localized its epitope to the smallest reactive band of »12 kDa. The largest positive band (1, »48 kDa) exhibited the same N-terminal amino acids as the negative band number 2 (»40 kDa), thus indicating that anifrolumab epitope lies within the C-terminal »8 kDa portion of this reactive fragment in subdomain 3 and/or 4. The second largest positive band number 4 (»23 kDa) contained 2 fragments (with similar abundance as estimated from Nterminal sequencing mass spectrometry) that spanned SD1-2 (cleaved at K 4 ) or SD3-4 with cleavage at K 184 having the N-terminal sequence 185 IGVYSPVH 192 . The smallest band number 5 (»12 kDa) also had 2 fragments with similar abundance that spanned SD1-2 (cleaved at K 98 with the N-terminal sequence 99 AQIGPPEV 106 ) and SD3-4 cleaved at residue K 240 with the N-terminal sequence 241 RNPGNHLY 248 . Although both positive bands numbers 4 and 5 contained 2 fragments, only the fragments in SD3-4 contributed to the binding of anifrolumab: Indeed, the corresponding SD1-2 fragments were not involved as confirmed by sequencing of the 2 large negative bands (numbers 2 and 3). In summary, results were consistent with anifrolumab epitope mapped to a »12 kDa fragment spanning SD3-4 with N-terminal residue R 241 .
Determination of anifrolumab epitope using deletion variants
An epitope mapping approach utilizing truncated mutants of the target protein provides an important tool to characterize functional epitopes at resolutions ranging from domain to single amino acid levels. 27 We further dissected the contribution of each subdomain of IFNAR1 that interacted with anifrolumab by generating truncated variants encoding a single (SD1, SD2, SD3, or SD4) or 2 tandem subdomains (SD1C2, SD2C3, or SD3C4). These deletion variants were transiently expressed as soluble proteins using mammalian cells and then characterized by western blot and surface plasmon resonance (SPR) using anifrolumab. Deletion variants encoding each individual subdomain or the tandem SD2-3 did not express (data not shown), probably owing to their misfolding. Indeed, tandem SD1-2 or SD3-4 have previously been shown to form domain 1 and 2, respectively, and as such are heavily inter-dependent in terms of overall fold. 15, 17 The expression of the variants encoding for SD1-2, SD3-4, or SD1-4 (full-length IFNAR1 ECD control) was detected by a polyclonal antibody specific to human IFNAR1 ( Fig. 2A and B , left panels). Anifrolumab recognized the truncated variant encoding SD3-4 and the full-length IFNAR1 ECD (SD1-4), but not the variant encoding SD1-2 under reducing and denaturing conditions in Western blots ( Fig. 2A) . Furthermore, the SPR study confirmed the binding of anifrolumab to the deletion variant SD3-4 with a K D of 280 pM, approximately 4-fold difference from that of the fulllength ECD SD1-4 (67 pM) under native conditions (Fig. 2B) . Therefore, this approach supported the enzymatic fragmentation data and confirmed that SD 3 or 4 are required and sufficient for anifrolumab binding.
Identification of specific binding motif in SD3 using phagedisplay peptide library approach Phage-display peptide libraries offer a quick and relatively straightforward approach to identify key epitope residues. 28 The Ph.D.
TM phage-display peptide library displaying Cys-constrained, randomized 7 amino acids was panned and screened against anifrolumab to identify mimotopes that mimic the structure of anifrolumab's epitope. Biopanning and ELISA screening was performed to identify phage clones that bound anifrolumab and competed with IFNAR1. Two mimotopes were identified: the YLXR/K consensus motif was found in 14 of 20 (70%) of (1, 4, and 5) . Western blot band number 4 after 15 min digestion appears as a so-called "ghost band" likely due to sample or detection antibody overloading as previously described. 42 A »38 kDa band observed in the untreated IFNAR1 lane of the western blot was not detectable in the SDS-PAGE gel. This band is likely a minor degradation product that pre-existed in the initial protein preparation and was digested into smaller fragments upon endoproteinase treatment. the positive peptides sequenced, and the LPWEKSR sequence motif was found in 6 of 20 (30%) of the peptides (Fig. 3) . The LPWEKSR motif did not match IFNAR1 sequence, suggesting it was a peptide binder unrelated to the antigen. However, the major consensus motif YLXR/K was localized to amino acids Y 276 L 277 R 279 in human IFNAR1 SD3. Notably, the peptide LRV [278] [279] [280] has been shown to be critical for IFNa-induced biologic activity, but not for ligand binding. 16 
Confirmation of the anifrolumab epitope in SD3 using chimeric variants
Loss-of-function (knock-out, "KO") chimeric variants can be used to scan regions for segments involved in the antibody/antigen binding interaction. Even more compelling, gain-of-function (knock-in, "KI") chimeric variants can be engineered, expressed and characterized to confirm the potential epitope regions identified by loss-of-function variants. The chimeric human/mouse IFNAR1 variant approach 29, 30 was applied to further refine the epitope of anifrolumab in SD3-4. Mouse IFNAR1 was chosen as a structural template to construct chimeric variants because it is not recognized by anifrolumab although it shares 46% homology with human INFAR1. The SD3 or SD4 of the full-length human IFNAR1 was replaced with the mouse counterparts to construct KO variants KO_SD3 and KO_SD4, respectively. The KI variants KI_SD3, KI_SD4, and KI_SD3-4 were generated by replacing subdomains of full-length murine IFNAR1 with their human counterparts. All chimeric variants expressed well as detected in a western blot using an antihuman IFNAR1 polyclonal antibody ( Fig. 4A-B) . anifrolumab did not bind to KO variant encoding mouse SD3 (KO_SD3). Consistently, anifrolumab recognized all variants encoding human SD3 (KO_SD4, KI_SD3, and KI_SD3-4, Fig. 4A ). Thus, these data support the finding that the epitope of anifrolumab is located in the SD3 subdomain.
To ) had no effect on the binding of anifrolumab (Table 1) . Furthermore, anifrolumab did not bind to the variant replacing amino acids 243-251 (KO_243-251), which was predicted by in silico modeling (see the "Proposed mode of interaction between anifrolumab and human IFNAR1" section) to localize in the binding interface with anifrolumab. However, anifrolumab did bind to the other 3 variants substituting mouse sequence for the peripherally localized stretches of residues encoded in KO_225-228, KO_252-257, and KO_284-287. Therefore, R 279 is a critical functional epitope residue that provides a dominant contribution to anifrolumab binding, and the positive-charged stretch of residues 243-251 ( 243 PGNHLYKWK 251 ) in proximity to R 279 also contributed substantially to the interaction with anifrolumab.
We have taken multiple approaches and employed several techniques, such as enzymatic fragmentation of IFNARI, phage-peptide library screening, and mutagenesis, approaches to thoroughly characterize the epitope of anifrolumab. Each approach has its own advantages and shortcomings, [27] [28] [29] [30] which is why several platforms were deployed. Overall, our epitope mapping results were consistent and complementary to each other.
Crystal structure of anifrolumab Fab
In the absence of an actual 3 dimensional structure, predicting an appropriate Fab crystal structure to perform IFNAR1 docking is challenging given the diversity of both the light and heavy chain CDR3. The complex formed between anifrolumab Fab and IFNAR1 did not form crystals; therefore, to provide guidance for protein docking calculations, the anifrolumab Fab was crystallized and the structure was determined at 2.3 A resolution. The atomic model is composed of amino acid residues 1-214 of the light (L) chain and residues 1-218 of the heavy (H) chain. Several C-terminal residues of both the light and the heavy 279 to mouse residues abolished the binding of anifrolumab, while replacing the other amino acids had no effect on anifrolumab binding.
chains, including the inter-chain disulfide bridge, have no corresponding electron density map and are rendered as disordered, and they were therefore omitted from the corresponding coordinate file. In addition to nearly 200 solvent molecules, a glycerol molecule, as well as potassium and phosphate ions present in the crystallization solution, were found to be coordinated by the Fab.
The Fab structure of 5-51/O12 (PDB ID 4KMT), a human germline antibody closely related to anifrolumab VH, was recently published. 31 There are 7 amino acids that differ between anifrolumab and 5-51/O12 heavy chains (germline IGHV5-51*01CIGHJ4) (Fig. 5A) : one in FR1, 2 are in CDRH1, and one each in FR2, CDRH2, FR3 and FR4. Superimposition of anifrolumab and 5-51/O12 VH domains (excluding CDR3H because it is not included in germline sequence) over Ca atoms shows 0.11 A root-mean-square deviations, rendering them as nearly identical (Fig. 5B) . The largest difference of 1.2A
in Ca positions appeared to be in the CDRH2 region.
Similarly, the VL domain of anifrolumab differs from the most closely related human germline with a known structure, IGKV3-20*01CIGKJ1*01, by 6 amino acids: 2 in CDRL1, 2 in FR3 and 2 in FR4 regions. The VL of corresponding PDB entry 4NP4 32 superimposes with anifrolumab VL very well, with an rms deviation of 0.15A (excluding CDR3L). Both germline VH and VL superimposed with anifrolumab are shown in Figure 5B .
anifrolumab CDR3H and CDR3L form a strongly negatively-charged 33 pocket at the center of the antigen binding region, whereas the periphery, which includes CDR1H, CDR1L, CDR2H and CDR2L, is also negatively charged, but to a lesser extent (Fig. 5C ).
Proposed mode of interaction between anifrolumab and human IFNAR1
Guided by the epitope mapping results, we used the ZDOCK 34 and RDOCK 35 algorithms to create a structural model of the anifrolumab Fab/IFNAR1 complex. The anifrolumab Fab crystal structure was docked to human IFNAR1 SD1-3 (PDB 3S98) using ZDOCK while excluding the constant domain of anifrolumab Fab and SD1-2 of IFNAR1. All predicted docked structures were clustered and processed by filtering for poses containing the critical functional epitope residue R 279 of IFNAR1 within 5A to anifrolumab. The resulted »100 poses were manually examined to deselect any poses predominantly involving the framework region of anifrolumab Fab for binding. The qualified »50 poses in 3 clusters were further refined and evaluated using RDOCK. All top poses with low RDOCK energies (< ¡14 kcal.mol ¡1 ), including electrostatic and desolvation energies, in each cluster were advanced for binding interface analysis. The final model was selected to be consistent with the epitope mapping mutagenesis results and the antagonistic property of anifrolumab, which blocks the binding of IFN-a 2a to IFNAR1-bearing Daudi B cells (Fig. 6) .
The interface between MEDI 546 Fab and IFNAR1 consists of 2 regions: one that is approximately 580 A 2 and formed between IFNAR1 and anifrolumab heavy chain ( Figure 7 , contact area 1), and another substantially smaller contact area that is approximately 160 A 2 . It is formed by both heavy and light chains interacting with IFNAR1 ( Figure 7 , contact area 2). For both of the interfaces, the contribution to binding by hydrophobic amino acids is small, with most of the binding conferred by charged residues. All three CDRs of the heavy chain participate in the larger interface with a particularly major contribution from CDRH2. The smaller interface region is dominated by CDRL3 with some contribution from CDRH2. The anifrolumab mechanism of action of preventing the formation of the ternary complex becomes apparent when the docked anifrolumab Fab/IFNAR1 model is superimposed with the crystal structure of human IFNAR1/IFNAR2/IFN through the common IFNAR1 molecule ( Figure 7B ). Upon binding to IFNAR1, the CDR1 and framework 3 region of anifrolumab light chain partially occupies the space of the IFN ligand in the ternary complex ( Figure 7B) . Therefore, anifrolumab blocks the formation of the ternary complex by inhibiting IFN ligand binding to IFNAR1 receptor and consequently preventing the heterodimerization with the IFNAR2 receptor. Notably, anifrolumab recognizes a unique antagonistic epitope in the SD3 of IFNAR1, while the previously reported IFNAR1-blocking antibodies all recognize the SD1 of IFNAR1.
Discussion
This work summarizes important new findings related to the function and design of therapeutic antibodies. More precisely, we provide a detailed molecular understanding of the interaction of a human monoclonal antibody directed against IFNAR1. This antibody, anifrolumab, is currently in clinical trials for the treatment of autoimmune disorders. To understand its neutralizing activity, we characterized the corresponding epitope using multiple approaches including enzymatic fragmentation, phage-display peptide library, and mutagenesis. We also solved the crystal structure of anifrolumab Fab, and then guided by the identified epitope, determined its mode of binding through protein docking. Interestingly, anifrolumab binds a novel, function-blocking epitope on SD3 of hIFNAR1, different from the previously reported IFNAR1-neutralizing epitopes in SD1. The SD1 of IFNAR1 is a common epitope region recognized by all of the reported IFNAR1 antagonistic mAbs. For example, Benoit et al. reported the first neutralizing antibody against IFNAR1, mAb 64G12, which provided evidence that this receptor chain is required for binding and signaling of all type 1 interferons. 22 Eid and colleagues then mapped the binding epitope of 64G12 by screening overlapping peptides covering SD1-2 and reported that the neutralizing mAb binds to the region of 62 FSSLKLNVY 70 in SD1 of hIFNAR1. 13 
Materials and Methods
Reagents and software
Plasmids encoding SD1-4 (amino acids or full-length (amino acids 1-530) human IFNAR1, human IFNAR1 with a 6 £ His tag (rhIFNAR1, amino acids 1-408), and anifrolumab were generated at MedImmune. Human and mouse IFNAR1 amino acid positions were denoted based on a numbering scheme of the mature protein without the signal peptide sequence (human IFNAR1, NCBI reference sequence NP_000620.2; mouse IFNAR1, NP_034638.2 ). Chinese www.tandfonline.com 435 mAbs hamster ovary (CHO) Lec1, murine lung epithelial (MLE-12) cells, Daudi cells, and RPMI 1640 medium were purchased from American Type Culture Collection. Minimum essential a (MEMa) medium, the vectors pFastBac TM and pcDNA3.1, lipofectamine TM 2000, phosphate buffered saline (PBS) pH7.4, and 293F cells were ordered from Invitrogen. Fetal bovine serum (FBS), SDS-PAGE gel, polyvinylidene difluoride (PVDF) membranes, Coomassie blue, milk powder, SuperBlock blocking buffer, chemiluminescent substrates, Nunc 96-well micro plates, immobilized papain, 5 ml protein L cartridge and elution buffer were purchased from ThermoFisher Scientific. Goat anti-IFNAR1 polyclonal antibody used in the Western blot analysis was from GeneTex. Anti-human and anti-mouse IFNAR1 polyclonal antibodies used in the ProteOn binding characterization were purchased from R&D Systems. Anti-human IgG-HRP and anti-goat IgG-HRP antibodies were purchased from Jackson ImmunoResearch. Endoproteinase Lys C was from Calbiochem/ Merck KGaA. Bovine serum albumin (BSA) was from SigmaAldrich. Cys-constrained 7-mer Ph.D.
TM phage-display peptide library was from New England Biolabs. Oligotex direct mRNA kit was purchased from Qiagen Sciences. ProteOn GLC chip, amine coupling kit, 10 mM sodium acetate buffer (pH 5.0), running buffer PBS (pH 7.4) with 0.005% (v/v) Tween-20, ProteOn XPR36 instrument, and ProteOn Manager 3.0.1 software were from BioRad. IODO-GEN Ò solid phase iodination reagent was from Pierce. Na 125 I was ordered from Amersham. Wizard 1470 gamma counter was purchased from Perkin Elmer. GraphPad Prism 4 software was purchased from GraphPad. Glass fiber plates were from EMD Millipore. Superdex S75 24 ml size exclusion chromatography (SEC) column and Vivaspin20 30 kDa cut-off concentrators were from GE Healthcare Bio-Sciences. Commercially available crystallization screens were from Hampton Research. HKL-2000 program package was from HKL Research, Inc.. Discovery Studio 3.5 and the corresponding ZDOCK, RDOCK and CHARMm applications were licensed from Accelrys.
Proteolytic fragmentation of IFNAR1
Proteolytic fragmentation of rhIFNAR1 was performed by incubating 15 mg rhIFNAR1 with 1 mg endoproteinase Lys C for 15 min, 1 h, and 26 h at room temperature. The resulted protein fragments were resolved on a 4-12% (w/v) reducing gradient SDS-PAGE gel and transferred to a PVDF membrane for western blotting then probed with anifrolumab. After staining the PVDF membrane with Coomassie blue, all protein bands were cut from the membrane, eluted and characterized by N-terminal Edman sequencing. 26 Phage-display peptide library screening and analysis The Cys-constrained 7-mer Ph.D.
TM phage-display peptide library was screened to select peptide binders to anifrolumab according to the following manufacturer's instructions: Briefly, Nunc 96-well plates were coated with anifrolumab (1 mg/ml) at 4 C overnight. These plates were subsequently washed in PBS pH 7.4 supplemented with 0.1% (v/v) Tween-20 (PBST) and then blocked with 3% (w/v) BSA in PBS for 1 h at 37 C. Plates were then incubated with 100 ml phage library (10 12 pfu/ml) in PBST for 1 h at room temperature, and then washed 10 times with PBST. Bound peptide-phages were competitively eluted with 100 ml of rhIFNAR1 at 100 mg/ml. After six rounds of panning, single clones were isolated and screened by phage ELISA. Nunc 96-well plates were coated with an anti-M13 monoclonal antibody (5 mg/ml), washed with PBST, and then blocked with 3% (w/v) BSA in PBS for 1 h at 37 C. Plates were then incubated with 50 ml phage-containing supernatants from the expression of single colonies and washed 10 times with PBST. anifrolumab (1mg/ml) or the pre-incubated mixture of anifrolumab (1 mg/ml) /rhIFNAR1 (20 mg/ml) was added to the wells. After washing, bound anifrolumab was detected using a goat anti-human Fc HRP-conjugated polyclonal antibody. Clones that showed ELISA signals in wells with anifrolumab, but not in the wells containing the anifrolumab/rhIFNAR1 mixture were selected and single-stranded DNA was prepared for sequencing.
Construction and expression of deletion and chimeric IFNAR1 variants
DNA encoding various subdomains of IFNAR1 (SD1, 2, 3, 4, 1-2, 2-3, or 3-4) were PCR-amplified using the pFastBac TM plasmid encoding full-length human IFNAR1 as a template. Mouse IFNARI cDNA was reverse transcriptase-PCR amplified from total mRNA isolated from MLE-12 cells using the Qiagen Oligotex direct mRNA kit. DNA encoding human/mouse chimeric IFNAR1 variants were assembled and amplified by overlapping PCR using human and mouse IFNAR1 DNA as templates. The amplified DNAs were then cloned into the mammalian expression vector pcDNA3.1. CHO Lec1 cells were transiently transfected with these 
constructs using Lipofectamine
Ò 2000 according to the manufacturer's instructions. Cell culture supernatants containing soluble protein from deletion variants, or cells expressing fulllength chimeric variants were harvested for western blot analysis at 2 days post-transfection.
Western blot
Cell culture supernatants containing soluble rIFNAR1 variants or cell lysates were resolved on a 4-12% (w/v) reducing gradient SDS-PAGE gel and transferred to PVDF membrane. The membrane was blocked with SuperBlock blocking buffer for 1 h at RT and incubated with 1 mg/ml anifrolumab in PBST containing 10% (v/v) SuperBlock blocking buffer. After washing 6 times with PBST, bound anifrolumab was detected with a goat anti-human Fc HRP-conjugated polyclonal antibody and revealed using a chemiluminescent substrate.
Characterization of anifrolumab binding to IFNAR1 variants using ProteOn
The binding characterization of anifrolumab to IFNAR1 variants were studied using a ProteOn XPR36 instrument. Standard amine coupling was used to immobilize an anti-human or anti-mouse IFNAR1 polyclonal antibody in 10 mM sodium acetate (pH 5.0) to the surface of a ProteOn GLC biosensor chip at »5000 resonance units (RU) for each channel. IFNAR1 variants in transfected cell supernatant were captured on the chip surface by an anti-IFNAR1 polyclonal antibody. The expression levels of the variants were normalized, using the appropriate dilutions to achieve comparable levels of ligand density. Untransfected cell supernatant was also injected under the same conditions as a reference channel. Anifrolumab samples were prepared in PBS (pH 7.4), 0.005% (v/v) Tween-20, and injected at 90 mL/min for 150 sec at concentrations ranging from 10 nM to 0.625 nM (1:2 dilutions) with a 500 sec dissociation time. Following the injection of anifrolumab, anti-IFNAR polyclonal antibody (30 nM to 1.875 nM, 1:2 dilutions) was injected to assess the expression levels of these variants under the same injecting conditions as anifrolumab. The sensor surface was regenerated by injecting glycine buffer (10 mM, pH1.5) at 100 mL/min for 30 sec, twice. For the kinetic analysis, sensorgram data were processed with the ProteOn Manager 3.0.1 software and fit to a bivalent model.
Competition binding between anifrolumab and IFN-a 2a to IFNAR1
Competitive binding of IFNa 2a and anifrolumab to IFNAR1 (expressed on Daudi cells) was demonstrated using a fixed concentration of radio iodinated IFN-a 2a ( 125 I-IFN-a 2a) and a titration of anifrolumab. IFN-a 2a was radio iodinated using IODO-GEN Ò solid phase iodination reagent (1,3,4,6-tetrachloro-3a-6a-diphenylglycouril; Pierce). Five mg of IFN-a 2a and 250 mCi of Na 125 I (Amersham IMS30-1mCi) were added to an iodo-gen tube and incubated for 7 min. Excess iodide was removed by using a desalting column, and fractions of labeled IFN-a 2a were collected and analyzed for radioactivity on a Wizard 1470 gamma counter.
Daudi cells were then incubated with 125 I-IFN-a 2a in the presence of serially diluted (50 nM to 64 pM) unlabeled IFNa2a, MEDI-546, 9D4 (the same Fab sequence as anifrolumab without the triple mutations (TM) L234F/L235E/P331S in the Fc region), or isotype control antibodies. Glass fiber plates were blocked with 200 mL/well milk buffer (PBS C 1% (w/v) milk powder) overnight at 4 C. Daudi cells in exponential growth phase were re-suspended in binding buffer and incubated with 2 nM 125 I-IFN-a 2a in the presence of 5-fold serially diluted MEDI-546, 9D4, unlabeled IFN-a 2a, or isotype control antibodies (50 nM to 64 pM) in the blocked glass fiber plates. The plate was gently agitated at 4 C for 2 hours, washed on a vacuum manifold with RPMI 1640 supplemented with 10% FBS (v/v) and 500 nM of sodium chloride and air-dried. The glass fiber filters were transferred to glass tubes and were analyzed for radioactivity on a Wizard 1470 gamma counter. Values were plotted to fit a non-linear regression 1-site competition curve using the GraphPad Prism 4 software; the corresponding IC 50 values were calculated accordingly.
Anifrolumab Fab purification, crystallization, data collection and structure determination
The Fab portion of anifrolumab was obtained through the cleavage of intact IgG using immobilized papain. Prior to use, the immobilized papain was activated in 20 mM sodium 37 C in 20 mM sodium phosphate, pH 7.0, 20 mM EDTA. The mixture containing Fab, Fc and traces of intact IgG was then loaded onto a 5 ml protein L cartridge. Fab and intact IgG bound to protein L and were eluted stepwise using IgG elution buffer (ThermoFisher Scientific) while the Fc portion was collected in the flow through. The solution containing Fab and undigested IgG was buffer-exchanged in 50 mM Tris, pH 7.5, concentrated, and loaded onto a Superdex S75 column. The Fab portion was collected, concentrated to 10 mg/ml using a Vivaspin20 (30 kDa cut off) concentrator and subjected to crystallization trials using commercial screens. Diffraction quality crystals grew in hanging drops in the presence of 200 mM potassium di-hydrogen phosphate, 100 mM MES, pH 6.5 and 20% (v/v) PEG 8000. Cryopreservation was achieved by supplementing the growth solution with 20% (v/v) glycerol prior to flash cooling in liquid nitrogen. Data were collected from a single crystal using a MicroMax-007 rotating anode generator fitted with an R-AXIS IV 2C imaging plate at 100 K. The diffraction images were integrated and scaled using HKL-2000. 36 The crystal diffracted to 2. . The crystal structure was solved using molecular replacement method as it is implemented in MolRep. 37 PDB ID number 1RHH 38 with the CDR residues removed was used as a template. One Fab molecule was found in the asymmetric unit with a corresponding Matthew's coefficient of 2.1 and 42% solvent content. The structure was refined using Refmac5 in the CCP4 suite. 39 Manual rebuilding was performed using "O."
40 Data and refinement statistics are presented in Table 2 .
Protein docking
The ZDOCK in DS 3.5 was used to dock human IFNAR1 to the anifrolumab Fab crystal structure. The coordinates of IFNAR1 SD1-3 were prepared for docking using PDB ID number 3S98 17 and the protein preparation tool in Discovery Studio 3.5. CHARMm force field 41 was applied throughout the simulation. Rigid-body docking was performed at a 6 angular step size and clustered for the top 2000 poses, excluding the constant domains of anifrolumab Fab and SD1-2 of IFNAR1. All poses from ZDOCK were processed by filtering for poses containing R 279 within 5A
to anifrolumab. The clusters with the highest density of poses were further considered and went through manual examination to deselect poses involving mainly the framework regions of anifrolumab for binding. The selected poses were then refined and evaluated using RDOCK. Only top poses with low RDOCK energies were advanced for binding interface analysis. All docking calculations were made with Discovery studio 3.5.
Accession number
The atomic coordinates and experimental structure factors of anifrolumab Fab have been deposited with the Protein Data Bank under accession number 4QXG.
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